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Vfr is a global regulator of virulence factor expression in the human pathogen Pseudomonas aeruginosa.
Although indirect evidence suggests that Vfr activity is controlled by cyclic AMP (cAMP), it has been hypoth-
esized that the putative cAMP binding pocket of Vfr may accommodate additional cyclic nucleotides. In this
study, we used two different approaches to generate apo-Vfr and examined its ability to bind a representative
set of virulence gene promoters in the absence and presence of different allosteric effectors. Of the cyclic
nucleotides tested, only cAMP was able to restore DNA binding activity to apo-Vfr. In contrast, cGMP was
capable of inhibiting cAMP-Vfr DNA binding. Further, we demonstrate that vfr expression is autoregulated and
cAMP dependent and involves Vfr binding to a previously unidentified site within the vfr promoter region.
Using a combination of in vitro and in vivo approaches, we show that cAMP is required for Vfr-dependent
regulation of a specific subset of virulence genes. In contrast, we discovered that Vfr controls expression of the
lasR promoter in a cAMP-independent manner. In summary, our data support a model in which Vfr controls
virulence gene expression by distinct (cAMP-dependent and -independent) mechanisms, which may allow P.
aeruginosa to fine-tune its virulence program in response to specific host cues or environments.
Pseudomonas aeruginosa is an opportunistic pathogen re-
sponsible for a variety of life-threatening infections in immu-
nocompromised individuals and those receiving critical care
(12). P. aeruginosa is the primary cause of morbidity and mor-
tality in individuals with cystic fibrosis, in whom it causes
chronic lung infection (6). Furthermore, indwelling medical
devices, severe wounds, burns, surgery, and corneal abrasion
predispose otherwise-healthy individuals to infection by this
organism (12). The ability of P. aeruginosa to cause infection
depends on the expression of an array of surface-exposed and
secreted virulence factors (40). Many of these factors are di-
rectly or indirectly controlled by the transcriptional regulator
protein Vfr (virulence factor regulator). Vfr positively regu-
lates production of exotoxin A (ETA or ToxA), type IV pili
(Tfp), a type III secretion system (T3SS), and the las quorum-
sensing system which, in turn, controls the expression of hun-
dreds of additional genes, including multiple virulence factors
(2, 4, 44, 54). In addition, Vfr negatively regulates flagellar
gene expression (10). A consensus Vfr binding sequence has
been proposed (24), and direct binding of Vfr to target pro-
moters has been demonstrated for several genes, including
those encoding ToxA (toxA), LasR (the las quorum-sensing
regulator), FleQ (the master regulator of flagellar biogenesis),
RegA and PtxR (regulators of toxA expression), and CpdA (a
cyclic AMP [cAMP] phosphodiesterase) (2, 10, 14, 16, 24).
While the global role of Vfr in regulating virulence gene ex-
pression has been established, the molecular mechanisms that
control Vfr activity and expression are not well understood.
Vfr is a member of the 3,5-cAMP receptor protein (CRP)
family of transcriptional regulators (55). The best-studied
member of this family is Escherichia coli CRP, which primarily
regulates genes involved in carbon metabolism (20). CRP func-
tions as a homodimer, and its activity is directly controlled by
the allosteric regulator cAMP; CRP undergoes a conforma-
tional change upon cAMP binding that enables the protein to
interact with target promoters in a DNA sequence-specific
manner (5, 26, 34–36, 43). CRP is also capable of binding
3,5-cGMP (3, 13, 49); however, structural studies indicate
that cGMP does not induce the necessary conformational
change required for CRP DNA binding (36). Although previ-
ous studies have demonstrated that Vfr and CRP have similar
affinities for cAMP in vitro (48), the roles of cAMP and other
cyclic nucleotides in Vfr function have not been directly exam-
ined.
P. aeruginosa encodes two intracellular adenylate cyclases
(CyaA and CyaB) responsible for cAMP synthesis (58). Mu-
tants lacking both cyaA and cyaB exhibit reduced virulence
factor expression and are severely attenuated in an adult
mouse model of acute pneumonia (47, 58). In addition, whole-
genome expression profiling revealed that the transcriptomes
of P. aeruginosa mutants defective in cAMP synthesis or lack-
ing vfr are nearly identical, suggesting that Vfr activity is de-
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pendent on cAMP availability (58). In support of this notion, a
previous study revealed that Vfr is capable of restoring
cAMP-dependent gene expression in an E. coli crp mutant.
However, CRP cannot complement a P. aeruginosa vfr mu-
tant, suggesting that Vfr and CRP are not functionally in-
terchangeable (48, 55).
The putative cAMP binding pocket of Vfr contains three
additional amino acids relative to that of E. coli CRP (4, 55).
While most of the residues involved in cAMP binding are
conserved, Vfr has a threonine residue at a position equivalent
to serine 128 (S128) of E. coli CRP (4). Mutational studies
have demonstrated that threonine substitution of CRP S128
results in CRP activation by both cAMP and cGMP (28).
Furthermore, a spontaneous Vfr mutant (VfrEQERS) lacking
5 amino acids (EQERS) in the cyclic nucleotide binding do-
main, including two critical cAMP binding residues conserved
among other CRP homologs, retained the ability to regulate
expression of a subset of virulence factors (4). Based on these
observations, it has been proposed that Vfr may respond to
cAMP, cGMP and/or other allosteric regulators (4, 55). While
there is currently no evidence that P. aeruginosa has the ability
to synthesize cGMP (16), it does produce cyclic diguanosine
monophosphate (c-di-GMP) and possibly cyclic diadenosine
monophosphate (c-di-AMP) (22, 25, 56). Recent findings in-
dicate that some members of the CRP family bind c-di-GMP,
which acts as a negative allosteric regulator (27, 51).
While the mechanism of allosteric regulation of Vfr activity
is unresolved, there is evidence suggesting that vfr expression is
controlled at the level of transcription. A previous study iden-
tified two putative Vfr binding sites upstream of the vfr gene
(centered at bp 67.5 and bp 39.5 relative to the transcrip-
tion start site) (24). Furthermore, it was demonstrated through
electrophoretic mobility shift assays (EMSAs) that Vfr could
specifically bind to a vfr promoter probe containing both pu-
tative sites (24). Although the role of these sites in vfr promoter
activity has not been tested, direct binding of Vfr to this region
suggests that vfr expression is autoregulated, as is the case for
E. coli crp (1, 8, 21).
In this study, we directly assessed the cyclic nucleotide re-
quirement for Vfr activity both in vitro and in vivo. We gener-
ated apo-Vfr by two independent methods and demonstrate
that Vfr binding to most target promoters specifically requires
cAMP. Other cyclic nucleotides did not support Vfr activity.
Furthermore, we show that high concentrations of cGMP in-
hibit the formation of Vfr-DNA complexes. Using DNase I
footprinting, we identified a novel Vfr binding site within the
vfr promoter distinct from the previously proposed binding
sites. In vitro transcription assays were employed to demon-
strate that both cAMP and Vfr are required for positive vfr
autoregulation. Finally, we provide evidence that the lasR pro-
moter is an exception to the cAMP requirement paradigm,
since cAMP was not required for Vfr binding to the lasR
promoter in vitro or for activation of the lasR promoter activity
in vivo. Taken together, our findings provide new mechanistic
insights into the complex cAMP/Vfr signaling pathway that
controls P. aeruginosa virulence.
MATERIALS AND METHODS
Bacterial strains, plasmids, and culture conditions. The strains and plasmids
used in this study are listed in Table 1. For routine passage, strains were grown
at 37°C in LB (Difco). For complementation experiments, pPa-vfr was main-
tained in P. aeruginosa with 30 g/ml carbenicillin (Cb). Bacterial growth in broth
culture was assessed based on the optical density at 600 nm (OD600).
P. aeruginosa strains PAK cyaA cyaB vfr and PAK lasR vfr were constructed by
introducing a deletion allele for vfr (encoded by the pEXGmvfr plasmid) onto
the chromosome of PAK cyaA cyaB and PAK lasR, respectively, using a previ-
ously described method (58). PAK lasR cyaA cyaB was constructed by sequen-
tially introducing deletion alleles for cyaA and cyaB (encoded by pEXGmcyaA
and pEXGmcyaB, respectively) onto the chromosome of PAK lasR.
Chromosomal transcriptional reporters were constructed by PCR amplifying
the vfr promoter region (bp 164 to 206 relative to the vfr transcriptional start
site [39]) and the lasR promoter region (bp 264 to 238 relative to the
predominant lasR T1 transcriptional start site [2]) from P. aeruginosa strain PAK
chromosomal DNA using oligonucleotides (see Table S1 in the supplemental
material; EcoRI and BamHI restriction sites are underlined) tailed with attB1 or
attB2 sequences for Gateway cloning into pDONR201 (Invitrogen). Both pro-
moter fragments encompassed known or predicted promoter elements and the
translational start sites of the corresponding genes. Promoter fragments were
removed from pDONR201 by digestion with EcoRI and BamHI and ligated into
the corresponding restriction sites of mini-CTX-lacZ (23). The resulting plas-
mids were used to integrate the promoter-lacZ fusions onto the chromosome at
a vacant CTX phage attachment site of wild-type and mutant P. aeruginosa
strains as described previously (23).
A toxA transcriptional reporter plasmid was constructed by PCR amplifying bp
500 to 100 relative to the toxA translational start codon from PAK chromo-
somal DNA with toxA rep 5 and toxA rep 3 oligonucleotides (see Table S1 in
the supplemental material; HindIII and BamHI restriction sites are underlined),
digesting with HindIII and BamHI, and ligating into the corresponding restric-
tion sites of the plasmid pR-lacZ to create pRtoxA-lacZ. pR-lacZ is a low-copy-
number lacZ transcriptional reporter plasmid (gift of Arne Rietsch [Case West-
ern Reserve University]). The pRtoxA-lacZ plasmid was transferred to
appropriate strains by conjugation (18) followed by selection on LB agar plates
containing 75 g/ml gentamicin (Gm) and 25 g/ml irgasan (Irg).
To create a P. aeruginosa vfr expression plasmid (pPa-vfr), the open reading
frame of vfr was PCR amplified from strain PAK genomic DNA using primers 5
vfr and 3 vfr (see Table S1 in the supplemental material) and cloned into
pMMBV1GW (16) using Gateway cloning (Invitrogen) by a previously described
method (58).
Plasmid templates used in the in vitro transcription assays were created by
cloning the vfr promoter region (bp 164 to 206 relative to the vfr transcrip-
tional start site [39]) and the lasR promoter region (bp 264 to 30 or 264 to
238 relative to the lasR T1 transcriptional start site [2]) upstream of the rpoC
transcriptional terminator in plasmid pOM90 (38) to create pOM90-vfr, pOM90-
lasR(264 to 30), and pOM90-lasR(264 to 238). The promoter fragments were
PCR amplified from strain PAK chromosomal DNA using oligonucleotides
tailed with BamHI and EcoRI restriction sites (see Table S1 in the supplemental
material), digested with BamHI and EcoRI, and ligated into the corresponding
restriction sites of pOM90. For the in vitro transcription assay, the predicted size
of the vfr transcript is 281 nucleotides; the predicted sizes of the lasR transcripts
are 102 and 132 nucleotides for the pOM90-lasR(264 to 30) template and 310
and 340 nucleotides for the pOM90-lasR(264 to 238) template.
Protein purification and generation of apo-Vfr. Purification of cAMP-Vfr,
CpdA, a mutant derivative of CpdA (CpdA-N93A), and P. aeruginosa RNA
polymerase holoenzyme (RNAP) was carried out as described previously (16, 52)
(see Fig. S1 in the supplemental material). Apo-Vfr was generated by two
independent methods. In the first approach, cAMP-Vfr was incubated with a
5-fold molar excess of purified CpdA or CpdA-N93A for 18 h at 23°C. In some
experiments, CpdA was inactivated by heating for 5 min at 95°C prior to incu-
bation with Vfr. In the second approach, bound cAMP was removed from Vfr by
denaturing Vfr protein (0.5 ml at 55 g/ml) by dialysis for 2 h at 4°C against
buffer (50 mM Tris-HCl [pH 7.0], 100 mM KCl, 50 mM NaCl, 1 mM dithiothre-
itol [DTT], 1 mM EDTA, 10% glycerol, 0.5% Tween 20) containing 6 M urea.
Vfr was refolded by sequentially reducing the urea concentration to 3 M, 2 M, 1
M, 0.5 M, and 0 M under the dialysis conditions described above in the absence
or presence of 50 M cAMP.
EMSAs. DNA promoter probes were generated by PCR using the indicated
oligonucleotides (see Table S1 in the supplemental material) and end labeled
using 10 Ci of [-32P]ATP (GE Healthcare) and 10 U of T4 polynucleotide
kinase (New England Biolabs). EMSAs were performed as previously described
(7). Briefly, probes (0.25 nM each) were incubated in binding buffer (10 mM Tris
[pH 7.5], 50 mM KCl, 1 mM EDTA, 1 mM DTT, 5% glycerol, and 100 g/ml
bovine serum albumin) containing 5 g/ml poly(2-deoxyinosinic-2-deoxycyti-
dylic acid) [poly(dI-dC); Sigma] for 5 min at 25°C. As noted below and in the
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figure legends, cAMP, cGMP, c-di-GMP, or c-di-AMP was also present. cAMP-
Vfr or apo-Vfr protein was then added at concentrations (indicated in figure
legends) for a final reaction volume of 20 l and incubated for an additional 15
min at 25°C. Samples were subjected to electrophoresis on a 5% polyacrylamide
glycine gel (10 mM Tris [pH 7.5], 380 mM glycine, 1 mM EDTA) at 4°C. Imaging
and data analyses were performed using an FLA-7000 PhosphorImager (Fuji-
film) and MultiGauge v3.0 software (Fujifilm). EMSAs were repeated a mini-
mum of two times, and representative gels are shown.
DNase I footprinting assays. A single end-labeled -32P-labeled double-
stranded DNA probe was generated by PCR in which one of the oligonucleotide
primers was modified (5 Amino-MC6; Integrated DNA Technologies) at the 5
end to prevent phosphorylation (see Table S1 in the supplemental material).
Probes were subsequently labeled as described above. Footprinting reaction
mixtures consisted of a single end-labeled probe (10 fmol) with 5 g/ml poly(dI-
dC) (Sigma) in DNase I reaction buffer (10 mM Tris [pH 8.0], 50 mM KCl, 2 mM
MgCl2, 0.5 mM DTT, 100 g/ml bovine serum albumin, 10% glycerol). cAMP-
Vfr was added for a final reaction volume of 25 l, and the mixture was incubated
for 15 min at 25°C. DNase I footprinting and DNA sequencing reactions were
performed as previously described (31, 41, 45).
In vitro transcription assays. Plasmid templates (2 nM) were incubated in the
absence or presence of refolded apo-Vfr (100 nM) and/or cAMP (100 nM) in 1
transcription buffer (40 mM Tris-HCl [pH 7.5], 150 mM KCl, 10 mM MgCl2,
0.01% Tween 20, and 1 mM DTT) containing 0.75 mM rATP, rGTP, and rCTP
for 10 min at 25°C. Purified P. aeruginosa RNA polymerase holoenzyme, known
to be largely 	70 saturated (52), was then added (10 nM) and the mixture was
incubated for 5 min at 25°C. Finally, 0.75 mM rUTP and 5 Ci [
-32P]CTP in 1
transcription buffer containing heparin (50 g/ml) were added for a final reaction
volume of 20 l, and transcription was allowed to proceed for 10 min at 30°C.
Reactions were terminated by adding 20 l of stop buffer (98% formamide, 20
mM EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol), heated to 95°C
for 5 min, and electrophoresed on 5% denaturing urea polyacrylamide gels.
Phosphorimaging and densitometry were performed using a FLA-7000
PhosphorImager (Fujifilm) and MultiGage v3.0 software (Fujifilm), respectively.
-Galactosidase assays. Overnight cultures of strains containing vfr or lasR
promoter-lacZ fusions were diluted 1:100 into LB and grown to an OD600 of 1 or
5, respectively. Cb (30 g/ml) and isopropyl--D-thiogalactopyranoside (IPTG;
40 M) were added to the medium as indicated in the figure legends. Strains
harboring both pRtoxA-lacZ and pPa-vfr were grown overnight in LB containing
30 g/ml Cb and 15 g/ml Gm, washed twice with deferrated (33) Bacto tryptic
soy broth (DTSB; Becton Dickinson), and inoculated into fresh DTSB contain-
ing 30 g/ml Cb, 15 g/ml Gm, and 40 M IPTG. Starting with a culture OD600
of 0.025, bacteria were grown for 8 h, and 1 ml of culture supernatant was
collected. For all samples, -galactosidase activity measurements were carried
out as described previously (32), except that optical density determinations were
made using a 96-well plate reader (Bio-Tek). Each assay was repeated at least
three times.
Western blot assays. Bacteria were grown as described for -galactosidase
assays. Whole-cell lysates and culture supernatants were prepared for detection
of Vfr and secreted ToxA, respectively, as previously described (16). All Western
blot assays were repeated a minimum of three times with independently derived
protein samples, and representative blots are shown.
Statistical analysis. The two-tailed unpaired t test was used for data compar-
ison where appropriate using Prism v5.0b (GraphPad Software).
RESULTS
Vfr binds target promoters with different affinities in vitro.
The nucleotide sequence and position of Vfr binding sites
within target promoters vary substantially (2, 10, 14, 16, 24). To
determine the affinity of Vfr for a representative set of target
TABLE 1. P. aeruginosa strains and plasmids used in this work
Construct Descriptiona Reference or source
P. aeruginosa strains
PAK Wild-type strain 50
PAK cyaA Nonpolar cyaA deletion 58
PAK cyaB Nonpolar cyaB deletion 58
PAK cyaA cyaB Nonpolar cyaA cyaB deletions 58
PAK vfr Nonpolar vfr deletion 58
PAK cyaA cyaB vfr Nonpolar cyaA cyaB vfr deletions This study
PAK lasR Nonpolar lasR deletion 57
PAK lasR vfr Nonpolar lasR vfr deletions This study
PAK lasR cyaA cyaB Nonpolar lasR cyaA cyaB deletions This study
Plasmids
pMMBV1GW Empty P. aeruginosa expression vector; Apr 16
pPa-vfr vfr encoded by pMMBV1GW This study
pDONOR201 Gateway cloning vector; Knr Invitrogen
pR-lacZ Low-copy-number plasmid for creating transcriptional fusions with lacZ; Gmr This study
pRtoxA-lacZ toxA promoter region (bp 500 to 100 relative to toxA translational start codon) in
HindIII and BamHI sites of pR-lacZ
This study
mini-CTX-lacZ Plasmid for chromosomal integration of promoter-lacZ transcriptional fusions; Tcr 23
mini-CTX-Pvfr-lacZ vfr promoter region (bp 164 to 206 relative to vfr transcriptional start site) in
EcoRI and BamHI sites of mini-CTX-lacZ
16
mini-CTX-PlasR-lacZ lasR promoter region (bp 264 to 238, relative to lasR T1 transcriptional start site)
in EcoRI and BamHI sites of mini-CTX-lacZ
This study
pEXGmGW Gateway-adapted suicide vector; Gmr 58
pEXGmvfr pEXGmGW carrying vfr deletion allele 58
pEXGmcyaA pEXGmGW carrying cyaA deletion allele 58
pEXGmcyaB pEXGmGW carrying cyaB deletion allele 58
pOM90 Plasmid template for in vitro transcription assays; Knr 38
pOM90-vfr vfr promoter region (bp 164 to 206 relative to vfr transcriptional start site) in
HindIII and BamHI sites of pOM90
This study
pOM90-lasR(264 to 30) lasR promoter region (bp 264 to 30 relative to lasR T1 transcriptional start site)
in HindIII and BamHI sites of pOM90
This study
pOM90-lasR(264 to 238) lasR promoter region (bp 264 to 238 relative to lasR T1 transcriptional start site)
in HindIII and BamHI sites of pOM90
This study
a Apr, ampicillin resistance marker; Knr, kanamycin resistance marker; Gmr, gentamicin resistance marker; Tcr, tetracycline resistance marker.
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promoters, we used quantitative EMSAs. Vfr protein was ex-
pressed in P. aeruginosa and isolated from cellular lysates using
a cAMP-agarose affinity purification column (see Fig. S1 in the
supplemental material). Specific promoter probes (Pvfr, PtoxA,
PregA, PptxR, PlasR, and PcpdA) encompassing known or pre-
dicted Vfr binding sites (2, 14, 16, 24) were generated by PCR.
For each binding assay, cAMP-Vfr was incubated with the
specific promoter probe (200 bp), a nonspecific control
probe (160 bp), and poly(dI-dC) and analyzed by native
polyacrylamide gel electrophoresis and phosphorimaging. The
addition of cAMP-Vfr had no effect on mobility of the non-
specific DNA probe (Fig. 1). In contrast, mobilities of the Pvfr,
PtoxA, PregA, PptxR, PlasR, and PcpdA promoter probes were re-
tarded in a Vfr concentration-dependent fashion, indicating
the formation of specific protein-DNA complexes (Fig. 1). The
fraction of probe that shifted as a function of Vfr concentra-
tion was used to calculate the apparent equilibrium constant
(Keq) for cAMP-Vfr binding. The apparent Keq for the pro-
moter probes varied over an 18-fold range (Table 2), with
cAMP-Vfr having the highest affinity for PlasR and PcpdA and
the lowest affinity for PtoxA. Interestingly, our results showed
two distinct PlasR shift products that were not previously re-
ported (2). The higher-mobility product (complex I) was the
predominant form at the highest cAMP-Vfr concentration
tested (113 nM), and the lower-mobility shift product (complex
II) was observed as the cAMP-Vfr concentration was reduced.
At the lowest cAMP-Vfr concentration examined (4 nM), com-
plex II was the dominant shift product detected. The reason for
the two distinct PlasR shift products is unclear; however, the
subtle change in mobility likely reflects a difference in the
conformation of the protein-DNA complex rather than varia-
tion in the number of Vfr molecules bound per probe.
Cyclic AMP is required for Vfr binding to vfr, regA, ptxR, and
cpdA promoter DNA. To determine the role of cAMP in Vfr
function, we used two different approaches to generate cAMP-
free Vfr (apo-Vfr). As a first approach, we incubated the
cAMP-Vfr complex overnight with a 5-fold molar excess of
purified P. aeruginosa CpdA (see Fig. S1 in the supplemental
material), a cAMP phosphodiesterase that degrades cAMP
(16). To determine whether CpdA treatment affected the abil-
ity of Vfr to form complexes with its target promoters, the Vfr
and CpdA mixture was used in EMSA experiments in the
absence or presence of exogenous cAMP. CpdA treatment
eliminated the formation of Vfr shift complexes with the Pvfr,
PregA, PptxR, and PcpdA promoter probes (Fig. 2, lane 3). Inter-
estingly, CpdA-treated Vfr was unable to form complex I with
PlasR but retained the ability to form complex II (discussed
below). When cAMP-Vfr was incubated overnight in the ab-
sence of CpdA (lane 2), with heat-inactivated CpdA (lane 4),
or with a catalytically inactive CpdA mutant (CpdA-N93A;
FIG. 1. EMSAs showing the specific DNA binding activities of
cAMP-Vfr to Pvfr, PtoxA, PregA, PptxR, PlasR, and PcpdA promoter probes.
Specific and nonspecific probes (0.25 nM each; note that the specific
activity of the nonspecific probe is lower than that of the specific
probes) were incubated in the absence () or presence of various
concentrations of cAMP-Vfr (113, 38, 13, and 4 nM) for 15 min
followed by electrophoresis and phosphorimaging. Mobilities of the
promoter probes, encompassing known (PtoxA, PregA, PptxR, PlasR, and
PcpdA) or predicted (Pvfr) Vfr binding sites, were retarded in a Vfr
concentration-dependent manner, indicating the formation of specific
protein-DNA complexes. The nonspecific probe (160 bp) is indicated
by an asterisk. cAMP-Vfr-dependent PlasR shift complexes I and II are
indicated by Roman numerals.
TABLE 2. Apparent Keq for cAMP-Vfr binding to promoter DNA
Promoter Keq SEM na
vfr 17.0 4.5 3
toxA 95.0 10.3 2
regA 23.0 1.4 2
ptxR 15.4 4.8 2
lasR 5.3 0.4 2
cpdA 7.5 1.9 2
a Number of replicates for each quantitative EMSA.
FIG. 2. Cyclic AMP and cyclic GMP differentially affect Vfr-DNA
binding activity as assessed in EMSAs. Lanes 1 and 2 represent pro-
moter probes (0.25 nM each) that were incubated in the absence or
presence of cAMP-Vfr, respectively, for 15 min followed by electro-
phoresis and phosphorimaging. Lanes 3, 5, 6, and 7 represent samples
in which the cAMP-Vfr complex was incubated with the cAMP phos-
phodiesterase CpdA prior to the addition of specific promoter probes.
As controls, cAMP-Vfr was also incubated with heat-inactivated CpdA
(*; lane 4) or a catalytically inactive CpdA mutant (N93A; lane 8).
Binding reaction mixtures contained no exogenously added nucleo-
tides (lanes 1 to 4 and 8), 50 M cAMP (lane 5), 1 mM cGMP (lane
6), or both nucleotides (lane 7). PlasR shift complexes I and II are
indicated by Roman numerals. The final concentration of Vfr protein
in the EMSAs was 13 nM (Pvfr and PcpdA) or 38 nM (PregA, PptxR, and
PlasR).
3556 FUCHS ET AL. J. BACTERIOL.
lane 8) (16), Vfr retained DNA binding activity. The latter
results indicate that the loss of Vfr-dependent DNA binding
was specifically associated with CpdA activity. The ability of
CpdA-treated Vfr to shift the Pvfr, PregA, PptxR, and PcpdA
probes was rescued by the addition of cAMP (50 M) to the
DNA binding reaction mixtures (lane 5). These results indicate
that cAMP is necessary for Vfr binding to Pvfr, PregA, PptxR, and
PcpdA.
To further assess the contribution of cAMP to Vfr function,
we generated apo-Vfr by a second, nonenzymatic approach.
Specifically, cAMP-Vfr was denatured in the presence of 6 M
urea and cAMP was removed by dialysis. Vfr was then refolded
by sequentially reducing the urea concentration in the absence
or presence of 50 M cAMP, and the DNA binding activity of
recovered Vfr was examined by EMSA. Whereas Vfr refolded
in the presence of cAMP retained the ability to bind the Pvfr
probe (Fig. 3, lane 2), Vfr refolded in the absence of cAMP
was unable to shift Pvfr (lane 3). These results are consistent
with those obtained with CpdA-treated Vfr (Fig. 2) and sug-
gest that refolding of Vfr in the absence of cAMP generates
apo-Vfr. Cyclic AMP restored the DNA binding activity of
refolded apo-Vfr for Pvfr in a concentration-dependent manner
(Fig. 3, lanes 4 to 11). A 50% shift of the Pvfr probe occurred
at 50 nM cAMP (lane 8), and the maximal shift was achieved
at 200 nM cAMP (lane 6). Taken together, these results dem-
onstrate that for a representative set of Vfr-dependent pro-
moters, cAMP is required for the DNA binding activity of Vfr.
Cyclic AMP-independent binding of Vfr to the lasR pro-
moter. In contrast to the Pvfr, PregA, PptxR, and PcpdA probes, our
EMSA studies suggest that both cAMP-Vfr and apo-Vfr bind
to the PlasR probe. As mentioned above (Fig. 2, lane 3), incu-
bation of cAMP-Vfr with CpdA eliminated formation of the
higher-mobility Vfr-PlasR complex (complex I); however, CpdA
treatment had no effect on the formation of the lower-mobility
complex (complex II). The addition of excess cAMP (50 M)
specifically restored formation of complex I (Fig. 2, lane 3
versus 5). Similar results were observed with refolded apo-Vfr;
in the absence of exogenous cAMP only complex II was de-
tected (Fig. 3, lane 3). The addition of exogenous cAMP to
refolded apo-Vfr resulted in the formation of complex I in a
concentration-dependent manner. For refolded apo-Vfr, 25
nM cAMP was sufficient to shift 50% of the PlasR probe (lane
9), and the maximal shift was achieved between 50 and 100 nM
cAMP (Fig. 3). These results indicate that Vfr is capable of
forming distinct complexes with PlasR in a cAMP concentra-
tion-dependent manner and suggest that cAMP-Vfr and apo-
Vfr may be responsible for the different PlasR shift products
(complex I and II, respectively). As such, it appears that PlasR
is a unique promoter in that Vfr can bind the PlasR probe in
vitro without being fully saturated with cAMP. Although the
two Vfr-PlasR shift products were also detected in EMSAs
using Vfr presumed to be cAMP saturated (Fig. 1), it is pos-
sible that Vfr was not fully occupied with cAMP at the lower
protein concentrations as a consequence of dilution. To test
the possibility that cAMP dissociates from the cAMP-Vfr com-
plex upon dilution, we examined the affinity of cAMP-Vfr for
PlasR and PcpdA at various dilutions by EMSA in the presence
of excess cAMP (50 M). The Keq for cAMP-Vfr binding to
PlasR and PcpdA was unaffected by the addition of excess cAMP
(see Fig. S2 in the supplemental material), and both conditions
gave results identical to those in Fig. 1, indicating that the
purified cAMP-Vfr complex is fully saturated with cAMP even
when diluted to low nanomolar concentrations. Taken to-
gether, these results indicate that Vfr forms distinct complexes
with PlasR in both a Vfr and cAMP concentration-dependent
manner.
Cyclic GMP inhibits the formation of Vfr-DNA complexes.
To address whether cGMP can regulate Vfr function, CpdA-
generated apo-Vfr was incubated with an excess of cGMP (1
mM). Whereas cAMP restores DNA binding activity of apo-
Vfr, cGMP was unable to restore Vfr binding to the Pvfr, PregA,
PptxR, or PcpdA probes (Fig. 2, lane 6). Furthermore, cGMP did
not support the formation of Vfr-PlasR complex I and appeared
to reduce formation of complex II, suggesting that cGMP in-
hibits Vfr DNA binding activity. To further examine this pos-
sibility, we conducted competition experiments by simulta-
neously adding both cAMP and cGMP to CpdA-generated
apo-Vfr protein. The presence of 50 M cAMP and excess
cGMP (1 mM) prevented Vfr from binding to the Pvfr, PregA,
PptxR, and PcpdA probes and inhibited formation of PlasR com-
plex I (Fig. 2, lane 5 versus 7). While addition of cGMP alone
inhibited formation of Vfr-PlasR complex II, it appears that
complex II was produced when both cGMP and cAMP were
present. Currently, we are unable to explain this discrepancy.
We next examined the effect of cGMP on Vfr binding to Pvfr,
PtoxA, and PlasR promoter probes using refolded apo-Vfr. Sim-
ilar to the results with CpdA-generated apo-Vfr, the addition
of cGMP alone was not sufficient to restore binding of apo-Vfr
to Pvfr and PtoxA, and it inhibited formation of Vfr-PlasR com-
plex II (Fig. 4, lane 4). Again, consistent with the above results,
the presence of both cAMP (50 M) and excess cGMP (1 mM)
prevented Vfr from binding to the Pvfr and PtoxA probes and
formation of Vfr-PlasR complex I (Fig. 4, lane 7).
To determine the amount of cGMP required for inhibition
of Vfr DNA binding activity, we conducted a titration experi-
ment using the Pvfr probe. Refolded apo-Vfr shifted 90% of
Pvfr in the presence of 100 nM cAMP (Fig. 5, lane 3), and 50%
inhibition of the shift complex required an 2,500-fold molar
excess of cGMP (250 M; lane 6). Vfr binding activity was
unaffected in the presence of a 300-fold molar excess of cGMP
FIG. 3. Cyclic AMP is required for the binding of apo-Vfr to Pvfr
and the formation of PlasR complex I but not PlasR complex II. EMSA
results show DNA binding activity of denatured Vfr (38 nM) that was
refolded in the presence (lane 2) or absence (lanes 3 to 11) of 50 M
cAMP. For lanes 4 to 11, DNA binding reaction mixtures (15-min
incubation) contained various concentrations of exogenous cAMP (left
to right, 800, 400, 200, 100, 50, 25, 12, and 6 nM). PlasR shift complexes
I and II are indicated by Roman numerals.
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(30 M; lane 9). While these results indicate that cGMP can
act as an inhibitor of cAMP-dependent Vfr DNA binding
activity in vitro, the high concentration of cGMP required is
unlikely to be achieved in vivo (see Discussion). Furthermore,
it remains to be determined whether cGMP acts as a compet-
itive or allosteric inhibitor.
The inhibitory effect of cGMP raised the question as to
whether other cyclic nucleotides affect the DNA binding activ-
ity of Vfr. When added alone (1 mM) to refolded apo-Vfr,
neither c-di-GMP nor c-di-AMP supported the formation of
Vfr-DNA complexes with the Pvfr, PtoxA, or PlasR promoter
probes (Fig. 4, lanes 5 and 6). In addition, neither signaling
molecule inhibited the formation of Vfr-DNA complexes in
the presence of cAMP (lanes 8 and 9). Thus, our data indicate
that these nucleotides are unlikely to play a direct role in
regulating Vfr function.
Vfr binds to a single site within the vfr promoter in vitro. The
vfr promoter region is predicted to encompass two putative Vfr
binding sites, centered at bp 67.5 and 39.5 relative to the
transcriptional start site (24) (Fig. 6A). However, binding to
either site has not been experimentally proven. Although both
sites were present in the Pvfr probe examined by EMSA (Fig. 1
and 6A), our data and those of a previous study (24) demon-
strate that only a single Vfr-dependent shift product is formed.
While not definitive, these results suggest that Vfr may bind to
a single site within Pvfr. To address this issue, DNase I foot-
printing of Pvfr was performed. In the presence of cAMP-Vfr,
a 32-bp sequence (bp 73 to 42 relative to the vfr transcrip-
tional start site) was protected from DNase I cleavage (Fig.
6B). The protected region partially overlapped the two previ-
ously predicted binding sites and the intervening sequence
(Fig. 6A). Within the protected region, enhanced cleavage sites
were detected at bp 61 and bp 50/51 (Fig. 6B). The size
of the footprint and spacing of the DNase I hypersensitivity
sites are consistent with Vfr footprints of the toxA, regA, ptxR,
fleQ, lasR, and cpdA promoters (2, 10, 14, 16, 24) and suggest
that Vfr also binds to a single site within Pvfr. We identified a
putative Vfr binding site (5-GGATCACAGTC:CTGATAGC
TGC) within the protected region by aligning the position of
the DNase I hypersensitivity sites with those found in other
published Vfr DNase I footprints (Fig. 6B; see also Fig. S3 in
the supplemental material). Enhanced DNase I cleavage is
associated with distortion of the helical DNA structure and
occurs at positions 5 and 6 within the conserved half-sites of
CRP and Vfr binding sequences (24) (see Fig. S3). CRP has
been shown to induce 40° bends at equivalent positions in its
target promoters (42), a distortion that likely accounts for
increased DNase I sensitivity.
The putative Vfr binding site (5-GGATCACAGTC:CTGA
TAGCTGC; underlined sequence portions are the conserved
half-sites to which Vfr is predicted to bind) identified in the vfr
promoter shares limited conservation with the proposed Vfr
consensus binding sequence (5-ANWWTGNGAWNY:AGW
TCACAT, where dimeric Vfr is predicted to bind two half-sites)
(24); however, the upstream half-site (TCACA) within the vfr
promoter is identical to the consensus downstream half-site, sug-
gesting that Vfr may tolerate a high degree of variability in the
organization of its target binding sites. While further analysis is
needed to confirm the exact Vfr binding site, our data support the
notion that Vfr binds to its own promoter at a single site.
To determine whether Vfr binding is sufficient for activation
of Pvfr, in vitro transcription assays were performed in the
absence and presence of cAMP and using refolded apo-Vfr,
RNA polymerase isolated from P. aeruginosa that is largely 	70
saturated (see Fig. S1 in the supplemental material), and a
plasmid template carrying the vfr promoter region (bp 164 to
206 relative to the transcriptional start) (Fig. 6A). A 	70-
dependent transcript (320 nucleotides [nt]), produced from
the plasmid backbone, was detected under all conditions and
served as a positive transcription control (Fig. 6C). Whereas a
faint band, corresponding in size to the predicted plasmid-
encoded vfr transcript (281 nt), was detected in the absence
of cAMP or Vfr, the presence of both refolded apo-Vfr and
cAMP (100 nM) increased the amount of the vfr transcript
11-fold as determined by densitometry. In addition, we also
observed a cAMP-Vfr-dependent transcript (115 nt) gener-
ated from the plasmid backbone that fortuitously served as an
internal control for cAMP-Vfr-dependent transcription. These
FIG. 5. Kinetics of cGMP inhibition of Vfr binding to Pvfr as de-
termined by EMSA. Samples contained Pvfr (0.25 nM) in the absence
(lane 1) or presence of refolded apo-Vfr (38 nM) with no exogenous
nucleotide added (lane 2), 100 nM cAMP (lane 3), or both 100 nM
cAMP and various concentrations of cGMP (lanes 4 to 10; 1,000, 500,
250, 125, 60, 30, and 15 M).
FIG. 4. Analysis of the nucleotide requirements for Vfr-DNA bind-
ing activity. Denatured Vfr that was refolded in the absence of cAMP
was used in EMSAs to examine the ability of apo-Vfr to bind Pvfr, PtoxA,
and PlasR probes in the presence of different nucleotides. EMSAs were
performed with no exogenous nucleotide added (lane 2) or in the
presence of 50 M cAMP (lane 3), 1 mM cGMP (lane 4), 1 mM
c-di-GMP (lane 5), or 1 mM c-di-AMP (lane 6). Lanes 7 to 9 represent
samples in which cAMP (50 M) was added in addition to 1 mM
cGMP, c-di-GMP, or c-di-AMP, respectively. The final concentration
of apo-Vfr in EMSAs was 38 nM for Pvfr and PlasR and 113 nM for
PtoxA. PlasR shift complexes I and II are indicated in lane 3.
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data, along with the EMSA and DNase I footprinting results,
suggest that binding of cAMP-Vfr to a single site in the vfr
promoter is sufficient to activate Pvfr in vitro.
vfr expression is autoregulated and cAMP dependent. The
finding that Vfr activates vfr transcription in vitro suggests that
Vfr is subject to autoregulation in vivo. To test this hypothesis,
-galactosidase activity was measured in wild-type and vfr mu-
tant strains from a lacZ transcriptional reporter carrying the
same vfr promoter fragment used for the in vitro transcription
assays (Fig. 6A). The reporter was introduced at the P. aerugi-
nosa chromosomal CTX phage attachment site (23). The
wild-type strain displayed 6-fold more reporter activity than
the vfr mutant (P  0.0001), indicating that Vfr positively
regulates its own expression (Fig. 7A).
To address the in vivo role of cAMP in Vfr regulation, vfr
promoter activity was measured in strains lacking one or both
of the endogenous adenylate cyclases (CyaA and CyaB) (Fig.
7A). While -galactosidase activity in the cyaA mutant was
unaffected, activity in the cyaB mutant was reduced by more
than 50% compared to the wild type (P  0.0001). Further-
more, activity in the cyaA cyaB double mutant was significantly
reduced (P  0.0001) to a level similar to that observed for the
vfr mutant. Reduction in vfr promoter activity corresponded to
reduced Vfr protein levels, as determined by Western blot
analysis (Fig. 7A, bottom panel). Thus, vfr expression is auto-
regulated and dependent on cAMP levels in vivo. Based on our
EMSA studies, the simplest interpretation is that cAMP is
required for Vfr DNA binding activity in vivo. Alternatively,
cAMP binding may stabilize Vfr and protect it from degrada-
tion.
FIG. 6. Binding of cAMP-Vfr to a single site within the vfr promoter is sufficient for activation of vfr transcription in vitro. (A) Diagram of the
vfr promoter region used as template for in vitro transcription reactions and in vivo promoter reporter (Pvfr-lacZ) assays. Numbering (in bp) is
relative to the previously identified (39) vfr transcription start site (indicated in bold type and marked by the arrow, which shows the direction of
transcription). Also indicated is the transcription start site for the divergently transcribed gene PA0653. Amino acid residues for partial coding
sequences of Vfr and the PA0653 gene product are shown. The previously predicted Vfr binding sites (24) (centered at bp 39.5 and 67.5) are
underlined, and the sequence that was protected from DNase I cleavage by cAMP-Vfr (shownn in panel B) is boxed. The locations of
oligonucleotide sequences (vfr probe 5 and vfr probe 3) used to generate Pvfr probes for EMSAs and DNase I footprinting are indicated by arrows.
(B) DNase I footprinting of the vfr promoter region by cAMP-Vfr. Samples contained a DNA fragment (0.4 nM) corresponding to bp 153 to
48 relative to the vfr transcription start site; the top strand of the DNA probe was radiolabeled on a single end. Prior to treatment with DNase
I, the DNA probe was incubated in the absence () or presence of cAMP-Vfr (114, 13, or 1 nM). DNase I-generated fragments were separated
by electrophoresis, and Maxam-Gilbert (AG) sequencing ladders were made using the same DNA. The sequence of DNase I cleavage altered
by cAMP-Vfr is indicated, the putative Vfr binding site is boxed, and the predicted half-sites are shown by vertical lines to the right of the sequence.
Numbers indicate the distance (in bp) relative to the transcription start site, and asterisks indicate positions of enhanced DNase I cleavage. (C) In
vitro transcription from Pvfr and PlasR. Assay mixtures contained 10 nM P. aeruginosa 	
70 RNAP and 2 nM plasmid DNA template containing bp
164 to 206 of Pvfr (relative to its transcription start site) or bp 264 to 30 of PlasR (relative to the lasR T1 transcription start site). Where
indicated, 100 nM refolded apo-Vfr and/or 100 nM cAMP was present. The lengths in nucleotides of transcripts from the Pvfr promoter (281 nt),
the 	70-dependent control transcript produced from the plasmid backbone (*; 320 nt), and a cAMP-Vfr-dependent transcript produced from the
plasmid backbone (#; 115 nt) are indicated.
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To distinguish whether cAMP affects Vfr transcriptional ac-
tivity or Vfr protein stability, we compared vfr promoter activ-
ity when Vfr was ectopically expressed from an IPTG-inducible
tac promoter to equivalent levels in the vfr mutant and in a
triple mutant strain lacking both adenylate cyclases and chro-
mosomal vfr (cyaAB vfr) (Fig. 7B). When expressed to levels
similar to those observed in a wild-type strain (Fig. 7B, bottom
panel), plasmid-encoded Vfr was sufficient to fully restore vfr
promoter activity in the vfr mutant. In contrast, plasmid-en-
coded Vfr did not substantially increase vfr promoter activity in
the cyaAB vfr triple mutant, demonstrating that intracellular
cAMP is required for Vfr activity in vivo. Taken together, our
results indicate that cAMP modulates the cellular levels of Vfr
protein via Vfr autoregulation.
Cyclic AMP is necessary for Vfr-dependent expression of
toxA. To examine the role of cAMP in regulating Vfr-depen-
dent virulence factor expression, we evaluated the transcrip-
tional activity of the toxA promoter. The regulation of toxA
expression is complex and involves numerous regulators, in-
cluding the products of the Vfr-dependent regA and ptxR genes
(11, 14). In addition, our EMSA experiments and previous
studies suggest that toxA expression is also directly regulated
by Vfr (11, 15, 24, 55); however, the role of cAMP in toxA
expression in vivo has not been tested. -Galactosidase assays
were used to measure toxA promoter activity in strains harbor-
ing a plasmid-borne toxA transcriptional reporter (pRtoxA-
lacZ). Consistent with published data (11), toxA promoter ac-
tivity was significantly reduced (P  0.0001) in the vfr mutant,
and ectopic expression of Vfr in this strain background was
sufficient to restore transcriptional activity to that of the wild-
type strain (Fig. 8). Expression from the toxA promoter was
also significantly reduced (P  0.0001) in the cyaAB vfr triple
mutant; however, complementation with plasmid-encoded Vfr
was not sufficient to restore wild-type promoter activity. To
determine whether toxA expression correlated with secretion
of the toxA gene product, ToxA, we assessed protein levels in
culture supernatants by Western blot analysis (Fig. 8, bottom
panel). Consistent with previously published data (11, 16, 55),
the vfr mutant did not secrete detectable levels of ToxA, and
plasmid-encoded Vfr complemented the vfr mutant phenotype
(Fig. 8, bottom panel). In contrast, ectopic expression of Vfr in
FIG. 7. In vivo vfr expression is autoregulated and cAMP depen-
dent. (A) Activity of the vfr promoter as measured in a -galactosidase
assay in wild-type (wt), vfr, cyaA, cyaB, and cyaA cyaB (cyaAB) mutant
strains containing the chromosomal Pvfr-lacZ reporter (n  4; standard
errors of the means are shown). Strains were grown in LB to an OD600
of 1. -Galactosidase activity (in Miller units) for the cyaB mutant (*)
and for the cyaA cyaB and vfr mutants (**) was significantly different
(P  0.001) compared pairwise to the activity for all other strains
shown. (B) -Galactosidase activity of Pvfr-lacZ in wt, the vfr mutant,
and the cyaA cyaB vfr (cyaAB vfr) triple mutant strains containing
empty vector or the same vector encoding Vfr (pPa-vfr) (n  4; stan-
dard errrors of the means are shown). Cultures were grown in LB
containing Cb (30 g/ml) and IPTG (40 M) to an OD600 of 1.
-Galactosidase activity for the indicated strains (*) was significantly
different (P  0.0001) than the activity for the wild-type strain and the
complemented vfr mutant. The bottom portions of panels A and B
show Western blot results with whole-cell lysates from the indicated
strains probed with Vfr-specific antiserum. Lysates were normalized
based on total cellular protein.
FIG. 8. Cyclic AMP is required for Vfr-dependent expression of
toxA and secretion of its gene product ToxA. (Top) Activity of the toxA
promoter as measured by a -galactosidase assay in wild-type (wt), vfr
mutant, and cyaA cyaB vfr triple mutant (cyaAB vfr) strains harboring
the pRtoxA-lacZ transcriptional reporter plasmid (n  6; standard
errors of the means are indicated). Strains also contained empty vector
or the Vfr expression plasmid (pPa-vfr). Samples were taken from
late-stationary-phase cultures grown in DTSB (low iron) containing 30
g/ml Cb, 15 g/ml Gm, and 40 M IPTG. -Galactosidase activities
for the indicated strains (*) were significantly different (P  0.0001)
than the activity for the wild-type strain and the complemented vfr
mutant. (Bottom) Trichloroacetic acid-precipitated supernatants from
cultures grown as described above were resolved by SDS-PAGE and
probed with ToxA-specific antiserum.
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the cyaAB vfr triple mutant was not sufficient to restore ToxA
secretion. Thus, like the vfr promoter, cAMP directly affects
Vfr-dependent transcription of toxA.
Cyclic AMP is not required for Vfr-dependent expression of
lasR in vivo. In contrast to the Pvfr, PtoxA, PptxR, PregA, and PcpdA
probes, our EMSA studies suggest that both apo-Vfr and
cAMP-Vfr can bind the PlasR probe in vitro. To evaluate the
role of cAMP in Vfr-dependent activation of lasR in vivo, we
constructed a chromosomal transcriptional reporter in which
the lasR promoter (bp 264 to 238 relative to the lasR T1
transcriptional start site) (Fig. 9A) was fused to lacZ. -Ga-
lactosidase activity from the lasR promoter reporter was then
compared for the wild-type strain, the vfr mutant, and the
double adenylate cyclase (cyaAB) mutant. As previously re-
ported (2), there was a significant reduction (P  0.0001) in
reporter activity in the vfr mutant compared to the wild-type
strain (Fig. 9B). In contrast, lasR promoter activity was unaf-
fected in the cyaAB double mutant. These data indicate that in
vivo expression of lasR does not require cAMP synthesis. We
previously showed that deletion of the P. aeruginosa cAMP
phosphodiesterase gene cpdA results in a 30-fold increase in
intracellular cAMP and a 12-fold increase in vfr expression
(16). To evaluate the effects of increased cAMP and Vfr pro-
tein levels on lasR expression, we measured lasR promoter
reporter activity in an isogenic cpdA mutant. Like the cyaAB
mutant, the cpdA mutant retained wild-type levels of reporter
FIG. 9. In vivo expression of lasR is dependent on Vfr but not cAMP. (A) Diagram of the lasR promoter region used to generate the lasR
promoter reporter (PlasR-lacZ). Numbering (in bp) is relative to the lasR T1 transcriptional start site (2). T1 and T2 transcriptional start sites are
indicated in bold type and marked by the arrow, which shows the direction of transcription. Amino acid residues for the partial coding sequences
of LasR and the upstream gene product PA1429 are shown. The Vfr binding site is underlined, and a putative lux box, associated with
quorum-dependent gene regulation, is boxed (2). The locations of oligonucleotide sequences used to generate the PlasR EMSA probe (lasR probe
5/lasR probe 3), the in vivo transcriptional reporter (lasR rep 5/lasR rep 3), and two different in vitro transcription templates (lasR tx 5/lasR tx1
3 and lasR tx 5/lasR tx2 3) are indicated by arrows. (B, top panel) -Galactosidase activity (in Miller units) measured from the chromosomal
PlasR-lacZ reporter in wild-type (wt) and vfr, cyaA cyaB (cyaAB), and cpdA mutant strains (means  standard error of the means; n  3). Strains
were grown in LB broth to an OD600 of 5. The asterisk signifies that -galactosidase activity of the vfr mutant is significantly different (P  0.0001)
compared pairwise to activity for the other strains shown. (Bottom panel) Western blot of whole-cell lysates normalized for total protein and
probed with Vfr-specific antiserum. (C, top panel) -Galactosidase activity from the PlasR-lacZ reporter in wt, vfr mutant, and cyaA cyaB vfr (cyaAB
vfr) triple mutant strains containing empty vector or the same vector encoding Vfr (pPa-vfr). Cultures were grown in LB containing Cb (30 g/ml)
and IPTG (40 M) to an OD600 of 5. Results are presented as means  standard errors of the means (n  3). The asterisks signify that the
-galactosidase activities of vfr and cyaA cyaB vfr mutant strains containing empty vector were significantly different (P  0.0001) compared
pairwise to activity for all other strains. (Bottom panel) Western blot of whole-cell lysates normalized for total protein and probed with Vfr-specific
antiserum. (D) -Galactosidase activity from the PlasR-lacZ reporter in the wt strain and lasR, lasR vfr (lasR vfr), and lasR cyaA cyaB (lasR cyaAB)
mutants (means  standard errors of the means; n  3). Strains were grown in LB to an OD600 of 5. The asterisk signifies that the -galactosidase
activity of the lasR vfr (lasR vfr) mutant is significantly different (P  0.0001) compared pairwise to activities of other strains.
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activity (Fig. 9B). Thus, the results of our in vitro studies
correlate with our in vivo finding that cAMP synthesis is not
required for Vfr to bind the lasR promoter. Furthermore, our
results indicate that while Vfr is required for lasR expression,
promoter activity is unaffected over a wide range of Vfr protein
levels (Fig. 9B, bottom panel) and cAMP concentrations. To
further confirm these results, we demonstrated that plasmid-
encoded Vfr is sufficient to restore lasR promoter activity in
both a vfr mutant and a cyaAB vfr triple mutant (Fig. 9C).
Vfr is not sufficient to activate 70-dependent transcription
from PlasR in vitro. To determine whether binding of apo-Vfr or
cAMP-Vfr is sufficient for activation of PlasR, we conducted in
vitro transcription assays in the absence and presence of re-
folded apo-Vfr and/or cAMP and using P. aeruginosa RNA
polymerase, which was largely 	70 saturated, and a plasmid
template carrying the lasR promoter region (bp 264 to 30
relative to the lasR T1 transcriptional start site) (Fig. 9A). No
lasR-specific transcripts (expected sizes of 102 and 132 nt) were
detected under any of the reaction conditions used (Fig. 6C).
However, both cAMP-Vfr-dependent and -independent con-
trol transcripts were produced from the vector backbone, in-
dicating that the transcription reactions worked as expected.
To rule out the possibility that lasR transcription is initiated at
a site downstream of the T1 and T2 sites identified by S1
nuclease protection assays (2), we created a second in vitro
transcription template carrying the same full-length promoter
fragment (bp 264 to 238 relative to the T1 transcriptional
start site) as used in the in vivo promoter reporter assays (Fig.
9A). Again, both control transcripts were produced from the
vector backbone, but lasR-specific transcripts were not de-
tected (data not shown). Taken together, these results suggest
that an additional factor(s) is required for Vfr-dependent ac-
tivation of lasR or that an alternative 	 factor (other than 	70)
is necessary for the recruitment of RNA polymerase to the lasR
promoter.
Expression from the lasR promoter was previously reported
to be cell density dependent, and a putative lux box associated
with quorum-sensing-dependent gene expression was identi-
fied within the lasR promoter (2). Given the possibility that
lasR may be autoregulated, we examined Vfr-dependent ex-
pression of the lasR promoter reporter in a lasR mutant (Fig.
9D). -Galactosidase activity in the lasR mutant was unaf-
fected compared to the wild-type strain. Furthermore, reporter
activity in a lasR vfr double mutant was indistinguishable from
the vfr mutant (Fig. 9A and D). To determine if LasR facili-
tates Vfr-dependent expression from the lasR promoter in vivo
in the absence of cAMP, we assessed promoter reporter activ-
ity in a lasR cyaA cyaB triple mutant. Again, lasR deletion did
not affect promoter reporter activity, indicating that a factor
other than LasR is likely to contribute to Vfr-dependent tran-
scription from the lasR promoter.
DISCUSSION
In this study, we demonstrate that cAMP acts as a positive
regulator of Vfr by promoting Vfr DNA binding to multiple
virulence gene promoters. Although we demonstrated that the
cyclic nucleotide specificity of Vfr is similar to that of E. coli
CRP, it is not clear whether the changes in protein structure
that occur in CRP in response to cAMP binding also occur in
Vfr. In CRP, binding of cAMP causes a series of transitions in
the protein structure that ultimately contribute to a reposition-
ing of the DNA binding domain to an orientation compatible
for specific interactions with DNA (34–36, 43). Although Vfr
and CRP are highly homologous (67% identical and 91% sim-
ilar) (55), it is possible that particular residue differences, such
as those within the Vfr nucleotide binding pocket (4, 55),
induce conformational effects that are different than those
occurring in CRP, resulting in unique interactions between Vfr
and RNAP and/or target promoter DNA. Ultimately, struc-
tural studies comparing cAMP-Vfr and apo-Vfr are needed to
determine the nature of the allosteric change induced by
cAMP and may provide insight as to why CRP cannot func-
tionally substitute for Vfr (48, 55). Further, we cannot formally
rule out the possibility that Vfr is controlled by an effector that
does not regulate CRP and is different from the cyclic nucle-
otides tested in this study.
We observed that Vfr-DNA binding activity was inhibited by
cGMP, which is a property that is also exhibited by CRP (3, 13,
49). However, the relevance of Vfr regulation by cGMP in vivo
is questionable, since inhibition of Vfr-DNA binding activity
required a 2,500-fold excess of cGMP when cAMP levels were
within a biologically relevant range (16, 17). Overall, there
have been few reports of the presence of cGMP in bacteria,
and thus a physiological role of this nucleotide in prokaryotes
has yet to be defined (29). The P. aeruginosa genome encodes
a single enzyme (CyaB) with homology to guanylate cyclase,
but we have shown that CyaB has adenylate cyclase activity and
possesses critical substrate-determining residues consistent
with ATP being the preferred substrate (17, 30). Although the
P. aeruginosa cyclic nucleotide phosphodiesterase CpdA was
shown to exhibit cGMP phosphodiesterase activity in vitro,
intracellular cGMP levels remained below the limit of detec-
tion (0.01 M) in mutants lacking cpdA (16). Taken to-
gether, these findings suggest that cGMP is unlikely to play a
biological role in Vfr control.
A potential control point in regulating the activity of the
cAMP/Vfr signaling pathway is at the level of vfr expression.
We have provided both in vivo and in vitro evidence that Vfr
regulates transcription from its own promoter and that vfr
expression is cAMP dependent. Our data demonstrate that
Vfr is a positive regulatory factor with respect to its own tran-
scription. In contrast, the E. coli crp promoter is negatively
autoregulated by CRP, except at high concentrations of cAMP,
where positive autoregulation has been reported (1, 8, 21). The
different modes of autoregulation displayed by the crp and vfr
promoters are presumably due to their different promoter ar-
chitectures and reflect their specific regulatory roles in E. coli
and P. aeruginosa (catabolite repression versus virulence factor
expression, respectively). Our DNase I footprinting result in-
dicates that cAMP-Vfr binds to a single unique site centered
approximately 58 bp upstream of the vfr transcriptional start
site. This spacing is similar to that of the secondary CRP
binding site (CRPII) responsible for positive crp autoregula-
tion (21), raising the possibility that transcriptional activation
by Vfr and CRP at these sites occurs by a similar mechanism.
In addition, the fact that Vfr binds a single unique region
within the vfr promoter in vitro was surprising, given how
closely the two predicted Vfr binding sites matched the con-
sensus sequence (24); this result suggests that some Vfr bind-
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ing sites may be difficult to predict based on bioinformatic data
alone.
Our observation that cAMP was not required for Vfr bind-
ing to the lasR promoter in vitro or for lasR promoter activity
in vivo provides an exception to our overall finding that ex-
pression of multiple virulence genes requires cAMP for Vfr
activation. While we cannot formally rule out the possibility
that P. aeruginosa produces low levels of cAMP by some other
mechanism, intracellular levels of cAMP are greatly reduced in
a cyaAB mutant compared to a wild-type strain (16, 17, 58).
Neither apo-Vfr nor cAMP-Vfr was sufficient to activate tran-
scription from the lasR promoter in vitro, suggesting that an
additional factor(s) is required for Vfr-dependent expression
of lasR, such as an additional transcriptional regulator or an
alternative sigma factor (different from 	70). We ruled out the
possibility that LasR itself regulates lasR and/or promotes Vfr-
dependent activation, as we observed no effect on lasR re-
porter activity in strains lacking lasR. An alternative candidate
is GacA, the transcriptional regulator of the GacS/GacA sig-
naling cascade involved in extracellular polysaccharide synthe-
sis and biofilm formation (19, 53). GacA was shown to regulate
lasR expression in vivo by an unknown mechanism (37), and
further experiments are needed to establish whether this reg-
ulator and/or other downstream factors are critical for regula-
tion of lasR by apo-Vfr.
Although the mechanism for apo-Vfr activation of lasR re-
mains to be determined, our findings may account for the
previously reported phenotypes of a Vfr mutant in which 5
amino acid residues from the putative cAMP binding domain
were deleted (VfrEQERS) (4). Beatson et al. showed that
plasmid-based expression of VfrEQERS in a vfr mutant re-
stored quorum-sensing-dependent production of elastase but
not Tfp-dependent twitching motility. To explain this phenom-
enon, those authors proposed that VfrEQERS might be re-
sponding to cGMP or another effector to differentially regulate
gene expression. Taking into account the findings presented in
our study, it is more likely that VfrEQERS, like apo-Vfr, acti-
vates lasR expression, which in turn would support the subse-
quent expression of downstream quorum-sensing factors like
elastase. Nevertheless, the results from both studies still raise
the question as to why the las quorum-sensing system is de-
pendent on Vfr but not cAMP. It is possible that the simulta-
neous activation of the cAMP-dependent and quorum-sensing-
dependent regulons is counterproductive under conditions that
alter intracellular cAMP levels.
Since Vfr activity is ultimately dependent upon the cellular
concentration of cAMP (except in the case of lasR regulation),
understanding the mechanisms by which cAMP levels are con-
trolled is critical to expanding our knowledge of virulence
factor regulation in P. aeruginosa. Currently, the environmen-
tal signals that trigger P. aeruginosa to upregulate or down-
regulate cAMP/Vfr-dependent virulence factor production are
not known. Given that multiple cAMP-dependent virulence
factors are required for acute P. aeruginosa infection and that
acute virulence factor inhibition is associated with chronic P.
aeruginosa infection, we hypothesize that bacterial cAMP syn-
thesis is stimulated upon encountering the host environment
but then is subject to downregulation upon onset of the chronic
state. We predict that intracellular cAMP fluctuations occur in
response to spatio-temporal host signals that are unique to the
environments encountered during acute and chronic infection.
Further, cAMP downregulation may occur prior to (or in ad-
dition to) the well-documented genetic inactivation of viru-
lence factors and their regulators (such as Vfr) that occurs
among chronic infection isolates (46). In terms of cAMP acti-
vation, we have shown that the Chp chemotaxis-like chemo-
sensory signal transduction system controls cAMP levels via
modulation of CyaB adenylate cyclase activity (17). Once
cAMP is synthesized, the results of the present study suggest
that Vfr regulates virulence promoters in either a cAMP-de-
pendent (ptxR, regA, and toxA) or cAMP-independent (lasR)
manner. The cAMP-dependent branch of the pathway, in com-
bination with vfr autoregulation, may serve as a signal ampli-
fication loop, whereby subtle changes in intracellular cAMP
can have large effects on gene expression. The cAMP-indepen-
dent branch may allow differential regulation of Vfr-depen-
dent (but not cAMP-dependent) systems, such as quorum
sensing. Ultimately, the cAMP signaling cascade is predicted to
be reset following CyaB activation by the cAMP phosphodies-
terase CpdA. Further investigation is needed to define envi-
ronmental cues responsible for activating cAMP/Vfr signaling
and the mechanisms by which these signals are integrated into
the pathway in an effort to understand the specific impacts on
virulence regulation in different phases of P. aeruginosa infec-
tion.
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